Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Net Income (2020 - 2025)

Gain Therapeutics has reported Net Income over the past 6 years, most recently at $17.9 million for Q4 2025.

  • Quarterly results put Net Income at $17.9 million for Q4 2025, up 576.05% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 111.34% YoY), and the annual figure for FY2025 was $2.3 million, up 111.34%.
  • Net Income for Q4 2025 was $17.9 million at Gain Therapeutics, up from -$5.3 million in the prior quarter.
  • Over the last five years, Net Income for GANX hit a ceiling of $17.9 million in Q4 2025 and a floor of -$8.1 million in Q2 2024.
  • Median Net Income over the past 5 years was -$4.5 million (2022), compared with a mean of -$2.4 million.
  • Biggest five-year swings in Net Income: plummeted 554.57% in 2021 and later skyrocketed 576.05% in 2025.
  • Gain Therapeutics' Net Income stood at $3.1 million in 2021, then surged by 313.28% to $12.7 million in 2022, then plummeted by 137.29% to -$4.7 million in 2023, then grew by 20.23% to -$3.8 million in 2024, then skyrocketed by 576.05% to $17.9 million in 2025.
  • The last three reported values for Net Income were $17.9 million (Q4 2025), -$5.3 million (Q3 2025), and -$5.8 million (Q2 2025) per Business Quant data.